University of Fribourg

Aethlon Medical's Hemopurifier Receives Ethics Approval for Cancer Trial in India

8 months ago

• Aethlon Medical's Hemopurifier has received ethics approval in India for a clinical trial targeting solid tumors resistant to anti-PD-1 therapies. • The trial will assess the safety, feasibility, and optimal dosage of Hemopurifier in patients with stable or progressive disease. • Hemopurifier aims to improve therapeutic response by removing tumor-produced extracellular vesicles from the bloodstream. • Aethlon anticipates beginning patient recruitment in Q4 2024, with the trial informing future oncology efficacy studies.

Immunotherapy Demonstrates Long-Term Survival Benefits in Multiple Cancers

8 months ago

• Immunotherapy shows promise in achieving long-term survival for advanced melanoma patients, with a 10-year melanoma-specific survival rate of 96% in responsive individuals. • In early-stage triple-negative breast cancer, immunotherapy combined with chemotherapy significantly improves the five-year overall survival rate compared to chemotherapy alone. • For muscle-invasive bladder cancer, neoadjuvant durvalumab plus chemotherapy leads to longer event-free and overall survival than chemotherapy alone. • Ongoing research aims to understand and overcome resistance mechanisms to immunotherapy, fostering collaboration between researchers and pharmaceutical companies.